ACM
PHAS

Altium Capital Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Altium Capital Management’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-775,000
Closed -$2.41M – 170
2021
Q3 		$2.41M Hold
775,000
– – 0.63% 66
2021
Q2 		$2.88M Hold
775,000
– – 0.67% 63
2021
Q1 		$2.68M Buy
+775,000
New +$3.15M 0.74% 56

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Altium Capital Management's PHAS Position: Q4 2021 in Review

Altium Capital Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2021, closing a stake of 775,000 shares — an estimated $2.41M sold.

Altium Capital Management first reported a position in PHAS in Q1 2021 and held it in 3 quarters. The position peaked at $2.88M in Q2 2021. 51 funds tracked by Wall St. Rank hold PHAS as of Q4 2021.

  • Altium Capital Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Altium Capital Management sold 775,000 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $2.41M.
  • Altium Capital Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Altium Capital Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $2.88M in Q2 2021.
  • 51 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Altium Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.